|1.||Frankel, Arthur E: 8 articles (08/2010 - 03/2002)|
|2.||Roodman, G David: 5 articles (04/2014 - 03/2004)|
|3.||Hogge, Donna E: 5 articles (08/2010 - 03/2002)|
|4.||Szmitkowski, Maciej: 5 articles (01/2007 - 05/2003)|
|5.||Mroczko, Barbara: 5 articles (01/2007 - 05/2003)|
|6.||Lantz, Chris S: 4 articles (03/2014 - 08/2004)|
|7.||Lopez, Angel F: 4 articles (02/2014 - 01/2008)|
|8.||Srivastava, Rupesh K: 4 articles (02/2012 - 01/2009)|
|9.||Wani, Mohan R: 4 articles (02/2012 - 01/2009)|
|10.||Pote, Satish T: 4 articles (02/2012 - 01/2009)|
03/20/2001 - "These results demonstrate that ILP with recombinant adenoviral vectors carrying the IL-3 beta transgene inhibits tumor growth in rats and suggest that cytokine gene therapy using this administration technique might be beneficial for clinical cancer treatment."
12/01/2006 - "The results show that while intratumoral IL-3 expression or RT alone caused a modest delay in TRAMP-C1 tumor growth, the combination was synergistic with 50% of mice being cured and developing a long-term, tumor-specific state of immunity. "
07/01/1990 - "The antitumor activity of the fluid was only eliminated when it was treated with anti-mouse IL-3 mAb. Since nonspecific resistance to tumors in mice stimulated with SSM appears to require Lyt 1+ T-cells, these results suggest that, in part, nonspecific resistance to tumors of mice stimulated with SSM may be developed through IL-3, which was produced by Lyt 1+ T-cells after SSM stimulation."
08/01/2000 - "In previous studies, interleukin-3 (IL-3) gene expression within murine tumors was shown to increase their response to irradiation through immune mechanisms. "
01/01/1999 - "This investigation is one of the first studies assessing serum levels of IL-3 in the cancer patients. "
11/01/1996 - "When the hematologic reconstitution of patients in groups 2 and 3 was compared with that of patients in group 1, the addition of IL-3 resulted in a significant improvement of multilineage hematopoietic recovery, lower transfusion requirements, a lower number of documented infections, and shorter hospitalizations. "
10/01/1993 - "In addition, levels of IL-3 were significantly greater in mice resistant to infection (P < 0.01). "
01/01/1988 - "The capacity of the spleen cells from these cured mice to produce IL-3 upon a challenge infection was similar to those of the resistant CBA mice. "
01/01/2015 - "PTX treatment restored the levels of IFN-γ, MIP-1β, and IL-3 that had been down-regulated by Pb infection. "
06/01/2014 - "CD41 expression on basophils is upregulated after in vivo IL-3 treatment and during infection with Nippostrongylus brasiliensis (Nb). "
|3.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/20/2014 - "We evaluated the expression of the interleukin 3 (IL-3) receptor α subunit (CD123), an established marker of acute myeloid leukemia stem cells, on CML LSPCs and the potential of targeting those cells with the humanized anti-CD123 monoclonal antibody CSL362. "
12/15/2005 - "Coexpression of MN1-TEL and IL-3, but not SCF, rapidly caused a fatal myeloproliferative disease rather than acute myeloid leukemia (AML). "
09/05/1996 - "Interleukin-3 (IL-3) stimulates in vitro blast cell proliferation in a consistent proportion of acute myeloid leukemia (AML) cases, however the degree of response varies from case to case and it is not related to the FAB subtype or to other clinical parameters. "
05/01/1995 - "We report the in vitro suppression of the IL-3-dependent MO-7 acute myeloid leukemia proliferation by an interleukin-3 antagonist. "
03/01/1995 - "Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia."
01/01/1998 - "Many clinical trials of IL-3 were conducted, which increased the platelet nadir counts and improved the recovery from thrombocytopenia at a dose of 5 micrograms/kg/day for 7 to 14 days. "
06/01/1996 - "Administration of 250 IU/kg/day of IFN-gamma in combination with 10(3) U/kg/day of IL-3, which alone had no effect on platelet counts, diminished the nadir for platelet count and shortened the duration of thrombocytopenia. "
01/01/1996 - "Is interleukin 3 active in anticancer drug-induced thrombocytopenia?"
11/01/1998 - "Interleukin 3 in the treatment of chemotherapy induced thrombocytopenia."
07/01/1997 - "Chemotherapy-induced severe thrombocytopenia in gynecologic oncology and its treatment with interleukin-3."
03/01/1994 - "The purpose of this study was to evaluate the in vitro effect of IL-3 on the growth of follicular small-cleaved-cell lymphoma (FSCCL). "
09/01/1999 - "We conclude that treatment with IL-3 has no clinical benefit in patients receiving ABMT for malignant lymphoma."
10/10/1996 - "Interleukin-3 increases the incidence of 5-azacytidine-induced thymic lymphomas in pBOR-Il-3 mice."
03/01/1996 - "The relationship between p53-mediated transactivation and apoptosis was probed in interleukin 3 (IL-3)-dependent DA-1 lymphoma cells. "
03/01/1996 - "In two patients with bone marrow involvement with lymphoma, IL-3 had no effect on FSCCL cells. "
|1.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|2.||Granulocyte Colony-Stimulating Factor (G-CSF)
|4.||Interleukin-6 (Interleukin 6)
|5.||Interleukin-1 (Interleukin 1)
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|8.||Interleukin-5 (Interleukin 5)
|9.||Interleukin-10 (Interleukin 10)
|1.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|3.||Drug Therapy (Chemotherapy)